325 related articles for article (PubMed ID: 16054370)
21. Inhibitors of Plasmepsin II-potential antimalarial agents.
Corminboeuf O; Dunet G; Hafsi M; Grimont J; Grisostomi C; Meyer S; Binkert C; Bur D; Jones A; Prade L; Brun R; Boss C
Bioorg Med Chem Lett; 2006 Dec; 16(24):6194-9. PubMed ID: 17000102
[TBL] [Abstract][Full Text] [Related]
22. New organofluorine building blocks: inhibition of the malarial aspartic proteases plasmepsin II and IV by alicyclic alpha,alpha-difluoroketone hydrates.
Fäh C; Hardegger LA; Baitsch L; Schweizer WB; Meyer S; Bur D; Diederich F
Org Biomol Chem; 2009 Oct; 7(19):3947-57. PubMed ID: 19763297
[TBL] [Abstract][Full Text] [Related]
23. Azole-based non-peptidomimetic plasmepsin inhibitors.
Kinena L; Leitis G; Kanepe-Lapsa I; Bobrovs R; Jaudzems K; Ozola V; Suna E; Jirgensons A
Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800151. PubMed ID: 30063266
[TBL] [Abstract][Full Text] [Related]
24. Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum.
Miura T; Hidaka K; Azai Y; Kashimoto K; Kawasaki Y; Chen SE; de Freitas RF; Freire E; Kiso Y
Bioorg Med Chem Lett; 2014 Apr; 24(7):1698-701. PubMed ID: 24631188
[TBL] [Abstract][Full Text] [Related]
25. Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin.
Hidaka K; Kimura T; Ruben AJ; Uemura T; Kamiya M; Kiso A; Okamoto T; Tsuchiya Y; Hayashi Y; Freire E; Kiso Y
Bioorg Med Chem; 2008 Dec; 16(23):10049-60. PubMed ID: 18952439
[TBL] [Abstract][Full Text] [Related]
26. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum.
Gutiérrez-de-Terán H; Nervall M; Ersmark K; Liu P; Janka LK; Dunn B; Hallberg A; Aqvist J
Biochemistry; 2006 Sep; 45(35):10529-41. PubMed ID: 16939205
[TBL] [Abstract][Full Text] [Related]
27. Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II.
Kiso A; Hidaka K; Kimura T; Hayashi Y; Nezami A; Freire E; Kiso Y
J Pept Sci; 2004 Nov; 10(11):641-7. PubMed ID: 15568678
[TBL] [Abstract][Full Text] [Related]
28. Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors.
Ahmed W; Rani M; Khan IA; Iqbal A; Khan KM; Haleem MA; Azim MK
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):673-8. PubMed ID: 20063996
[TBL] [Abstract][Full Text] [Related]
29. Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution.
Miura T; Hidaka K; Uemura T; Kashimoto K; Hori Y; Kawasaki Y; Ruben AJ; Freire E; Kimura T; Kiso Y
Bioorg Med Chem Lett; 2010 Aug; 20(16):4836-9. PubMed ID: 20634066
[TBL] [Abstract][Full Text] [Related]
30. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors.
Luksch T; Chan NS; Brass S; Sotriffer CA; Klebe G; Diederich WE
ChemMedChem; 2008 Sep; 3(9):1323-36. PubMed ID: 18752222
[TBL] [Abstract][Full Text] [Related]
31. Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor.
Gutiérrez-de-Terán H; Nervall M; Dunn BM; Clemente JC; Aqvist J
FEBS Lett; 2006 Oct; 580(25):5910-6. PubMed ID: 17045991
[TBL] [Abstract][Full Text] [Related]
32. Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations.
Valiente PA; Batista PR; Pupo A; Pons T; Valencia A; Pascutti PG
Proteins; 2008 Nov; 73(2):440-57. PubMed ID: 18442137
[TBL] [Abstract][Full Text] [Related]
33. Starving the malaria parasite: inhibitors active against the aspartic proteases plasmepsins I, II, and IV.
Hof F; Schütz A; Fäh C; Meyer S; Bur D; Liu J; Goldberg DE; Diederich F
Angew Chem Int Ed Engl; 2006 Mar; 45(13):2138-41. PubMed ID: 16502446
[No Abstract] [Full Text] [Related]
34. Functional profiling, identification, and inhibition of plasmepsins in intraerythrocytic malaria parasites.
Liu K; Shi H; Xiao H; Chong AG; Bi X; Chang YT; Tan KS; Yada RY; Yao SQ
Angew Chem Int Ed Engl; 2009; 48(44):8293-7. PubMed ID: 19784986
[No Abstract] [Full Text] [Related]
35. Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors.
Savarino A; Cauda R; Cassone A
J Infect Dis; 2005 Apr; 191(8):1381-2; author reply 1382-3. PubMed ID: 15776390
[No Abstract] [Full Text] [Related]
36. Identification of acridinyl hydrazides as potent aspartic protease inhibitors.
Azim MK; Ahmed W; Khan IA; Rao NA; Khan KM
Bioorg Med Chem Lett; 2008 May; 18(9):3011-5. PubMed ID: 18417344
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and in vitro evaluation of gold(I) thiosemicarbazone complexes for antimalarial activity.
Khanye SD; Smith GS; Lategan C; Smith PJ; Gut J; Rosenthal PJ; Chibale K
J Inorg Biochem; 2010 Oct; 104(10):1079-83. PubMed ID: 20621360
[TBL] [Abstract][Full Text] [Related]
38. Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library.
Carroll CD; Patel H; Johnson TO; Guo T; Orlowski M; He ZM; Cavallaro CL; Guo J; Oksman A; Gluzman IY; Connelly J; Chelsky D; Goldberg DE; Dolle RE
Bioorg Med Chem Lett; 1998 Sep; 8(17):2315-20. PubMed ID: 9873534
[TBL] [Abstract][Full Text] [Related]
39. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
Dali B; Keita M; Megnassan E; Frecer V; Miertus S
Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
[TBL] [Abstract][Full Text] [Related]
40. Exploiting Structural Dynamics To Design Open-Flap Inhibitors of Malarial Aspartic Proteases.
Bobrovs R; Jaudzems K; Jirgensons A
J Med Chem; 2019 Oct; 62(20):8931-8950. PubMed ID: 31062983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
